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Previewssignaling is one downstream target of
Ahr in controlling the numbers of Rorgt+
ILCs; however, experiments in which
Notch1 or Notch2 are specifically deleted
in Rorgt+ ILCs are needed to verify this
point.
As indicated above, Ahr also affects
production of IL-22. Investigating the
underlying mechanism, Qiu et al. (2012)
found that the Il22 locus contained
multiple Ahr-responsive elements that
were clustered with Ror-responsive ele-
ments. Further analysis by chromatin
immunoprecipitation provided evidence
that both Rorgt and Ahr bind directly
to their response elements in the Il22
locus. Recruitment of Ahr to the Il22
locus but not to the locus of another Ahr
target, Cyp1a1, was strongly enhanced
by Rorgt. The corecruitment of Ahr and
Rorgt to the Il22 locus explains why
these factors synergistically enhance IL-
22 expression.In conclusion, Ahr is emerging as a
sentinel that guarantees optimal survival
and function of innate and adaptive
immune cells in the gut. This sentinel
needs to be fed continuously by endoge-
nous ligands and ligands derived from
dietary products. Ahr may be an inter-
esting target for therapeutic intervention
in inflammatory bowel diseases. This re-
quires knowledge of how Ahr affects the
function of IEL and Rorgt+ ILCs in the
human gut. In addition, future research
should be aimed at elucidating the relative
importance of dietary and endogenous
Ahr ligands in regulating immunity.
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Type I interferon is a family of antiviral cytokines linked to human autoimmune diseases. In this issue of
Immunity, Gall et al. (2012) characterize, in a murine model of autoimmunity, the origin and progression of
the type I interferon response leading to disease.Detection of nucleic acids and induction of
type I interferons (IFNs) are fundamental
steps in antiviral defense. Type I IFN
production is normally transient, and
chronic activation of this pathway by
host-derived DNA and RNA has been
associated with the development of auto-
immune diseases, such as systemic lupus
erythematosus (SLE), dermatomyositis
(DM), and type 1 diabetes (Banchereau
and Pascual, 2006). Negative regulation
of type I IFN production must therefore
be in place to prevent unwanted inflam-
mation (Richards and Macdonald, 2011).
Increased IFN production has also re-cently been recognized as a central path-
ogenic event in a group of rare Mendelian
disorders including Aicardi-Goutieres
syndrome (AGS), a severe inflammatory
disorder affecting primarily the brain and
skin, that mimics congenital viral infec-
tions and may share overlapping features
with SLE (Crow, 2011). In this issue of
Immunity, Gall et al. (2012) characterize
the origin and progression of the type I
interferon response and the downstream
mechanisms leading to autoimmune
disease in a murine model of AGS.
Both extracellular and intracellular
nucleic acids can trigger IFN productionby binding to endosomal and cytosolic
sensors, respectively. Extracellular nu-
cleic acids are recognized by endosomal
Toll-like receptor 3 (TLR3), TLR7, and
TLR9, which are expressed on antigen-
presenting cells and a few other cell
types. Although type I IFNs can be
produced in small quantities by virtually
every cell, the specialized plasmacytoid
dendritic cells (pDCs) stand out for their
ability to swiftly produce large amounts
of these cytokines upon TLR triggering.
Cytosolic nucleic acids are sensed by
ubiquitously expressed, cell-intrinsic re-
ceptors that trigger Type I IFN responses36, January 27, 2012 ª2012 Elsevier Inc. 7
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Figure 1. Myocarditis and Nephritis in TREX1-Deficient Mice Are Type I IFN- and
Lymphocyte Dependent
Absence of TREX1 in nonhemopoietic results in cell-intrinsic activation of yet uncharacterized cytosolic
DNA sensors. These sensors signal through STING-TBK1, leading to the phosphorylation and nuclear
translocation of IRF3 and subsequent transcription of type I IFN genes. Unabated type I IFN production
is necessary, but not sufficient to cause inflammation in Trex1/ mice. Lymphocytes are the mediators
of inflammation, given that Trex1/Rag2/ mice are disease free. Type I IFN-exposed T cells induce
inflammation and fibrosis in the heart (myocarditis) as well as in the interstitial areas of the kidneys of
Trex1/ mice. B cells and autoantibodies contribute to enhance the autoimmune pathology.
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Previewsin every infected cell of the body. Engage-
ment of both types of receptors results in
the activation of signaling pathways
leading to the nuclear translocation of
transcription factors, including NF-kB
and interferon regulatory factors (IRF3
and IRF7), and the subsequent tran-
scription of genes encoding IFN-a and
IFN-b. Secreted IFN proteins bind to
surface IFNAR1 and IFNAR2 receptors,
which are expressed on most nucleated
cells, and trigger a signaling cascade
resulting in the transcription of hundreds
of IFN-stimulated genes (ISGs).
Unabated activation of the TLR
pathway is considered to play a critical
role in the pathogenesis of SLE. Thus,
host-derived DNA and RNA complexed
with autoantibodies and/or endogenous
cationic proteins such as LL37 are inter-
nalized by pDCs and elicit activation of
TLR7 and TLR9 leading to IFN release
(Gilliet et al., 2008). Autoimmune diseases
may also result from defects in the
negative regulation of cytoplasmic, cell-
intrinsic, DNA signaling pathways. In this
context, Stetson et al. (2008) identified
Trex1 (DNase III), a major 30/50 DNA8 Immunity 36, January 27, 2012 ª2012 Elsevexonuclease of mammalian cells (Lindahl
et al., 1969), as a negative regulator of
this cytosolic pathway. Although TREX1
was originally thought to participate in
DNA replication, TREX1 null mice did
not show an increased spontaneous
mutation frequency. Instead, these mice
died prematurely as a result of inflam-
matory myocarditis and subsequent cir-
culatory failure (Morita et al., 2004).
Stetson et al. proposed that an accu-
mulation of ssDNA derived from endo-
genous retroelements, otherwise meta-
bolized by functional TREX1, was
responsible for the inflammatory pheno-
type observed in these mice. A series
of genetic crosses revealed that the
development of disease was independent
of TLR activation but required signaling
through IRF3 and an intact type I
IFN response. Crossing of TREX1-defi-
cient mouse with RAG2-deficient mice
showed that inflammation was dependent
on antibody production (Stetson et al.,
2008).
Gall et al. (2012) use six genetic crosses
to further explore the mechanisms lead-
ing to inflammation in TREX1-deficientier Inc.mice (Figure 1). Furthermore, they use a
reporter system to track in vivo the origins
and progression of the type I interferon-
mediated autoimmune disease in these
mice. First, crossing TREX1-deficient
mice to MAVS- or STING-deficient mice
demonstrates that mortality and autoim-
munity are dependent on STING sig-
naling, thus concluding that TREX1 is
a specific and essential negative regu-
lator of the STING-dependent interferon
pathway. It remains to be determined
whether any of the recently identified
cytosolic STING-dependent DNA sen-
sors, such as IFI16 or the helicase
DDX41 (Zhang et al., 2011), are con-
nected to this pathway. Next, the genera-
tion of Trex1+/ controls and Trex1/
mice with an in vivo reporter of IFN activity
allows them to determine that the IFN
response is an upstream event driving
disease in these mice. In fact, this re-
sponse starts in utero and precedes
any lymphocyte-dependent inflammation
and tissue damage. Evidence of IFN
signaling also appears on a Rag2/
background, demonstrating that the
IFN response is independent of lym-
phocytes. A detectable IFN response
occurs also shortly after birth in the heart,
in a restricted area near the endocardial
surface, suggesting a process that drives
the IFN response specifically in these
nonhematopoeitic cells before the
appearance of an inflammatory infiltrate
within the target tissue.
The use of mixed bone marrow
chimeras further allows the authors to
show that type I IFNs produced by the
initiating cells signal to hematopoietic
cells. IFN signaling is required to drive a
T cell-dependent inflammation and auto-
antibody response that result in a rapidly
progressing autoimmune destruction of
the target tissue. Along these lines,
genetic deletion of Tcra or Ighm rescues
the mice from mortality, showing that
both T cells and B cells contribute to the
autoimmune disease in Trex1-deficient
mice. T cells are necessary and sufficient
for the tissue-specific autoimmune
inflammation, including interstitial kidney
inflammation and fibrosis, whereas B cells
are not required for either of these key
disease features. However, B cells con-
tribute to the acceleration of morbidity
and mortality. They are also essential
for the development of membranoproli-
ferative glomerulonephritis, one of the
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mice. Thus, as in SLE, Trex1/ mice
developed antinuclear autoantibodies
(ANA), progressive IgG deposition in
kidney glomeruli, and inflammation.
However, no antichromatin IgG or dsDNA
autoantibodies develop in these mice.
Instead, Trex1/ mice reproducibly
develop autoantibodies to two abundant,
heart-specific, cytosolic proteins: cardiac
myosin (Myh6) and junctophilin-2 (Jph2).
The pathogenic role of these autoanti-
bodies has not been established, how-
ever, because no evidence for inflam-
mation in wild-type mice injected with
Trex1/ sera was apparently found.
Overall, this work provides a detailed
account of events leading to autoimmu-
nity in the context of Trex1 deficiency
and type I IFN-mediated autoimmunity.
This has important implications for under-
standing human AGS and some related
and more common interferonopathies,
including SLE and DM.
Humans AGS is not always caused
by mutations in Trex1. Indeed, the
syndrome is genetically heterogeneous,
with five loci (AGS1-5) having been
identified so far. AGS1-4 corresponds
to (TREX1), RNASEH2B, RNASEH2C,
and RNASEH2A mutation, respectively.
AGS5 was recently identified as a muta-
tion in the gene encoding SAMHD1,
a dNTP hydrolase highly expressed in
dendritic cells that inhibits HIV1 reverse
transcription and cDNA synthesis. Thus,
all the genetic contributors to AGS
participate in removing nucleic acids
that may represent either waste or the
product of reverse transcription of
endogenous or exogenous viruses and
therefore could trigger cell-intrinsic type
I IFN responses. Heterozygous TREX1
mutations have been described in a cuta-
neous form of SLE known as familial
childblain lupus (FCL), in rare cases of
dominantly inherited AGS and in patientswith an adult-onset cerebro-retinal
microangiopathy associated with Ray-
naud’s phenomenon retinal vasculopathy
with cerebral leukodystrophy (RVCL).
Furthermore, supporting the phenotypic
and biochemical overlap of AGS with
lupus, heterozygous TREX1 mutations
were found in up to 2% of SLE patients,
thus representing the single most
frequent cause of monogenic lupus
described so far (Crow, 2011). Interest-
ingly, most of the pathology found in
Trex1/ mice, especially myocarditis
and skeletal muscle inflammation, is not
seen in humans with AGS. In turn, the
cardinal symptoms of AGS, including
severe neurological involvement, are
missing in these mice. Myocardial
involvement is not uncommon however
in SLE, as evidence of myocarditis can
be found at postmortem examination in
40% of patients. Other clinical features
of Trex1/ mice such as skeletal muscle
inflammation and dermatitis are seen in
human SLE and DM, whereas interstitial
and glomerular kidney inflammation are
cardinal features of SLE.
Trex1/ mice are teaching us that
accumulation of nucleic acids in nonhe-
matopoietic cells drives disease through
a TLR-independent, intrinsic production
of type I IFN. Although this is very relevant
for the design of therapeutic strategies
for AGS as well as SLE patients with
TREX-related mutations, defective extra-
cellular DNA degradation has also been
linked to sporadic and familial cases of
SLE (Al-Mayouf et al., 2011 ; Yasutomo
et al., 2001). Furthermore, extrinsic
nucleic acid sensing through TLRs,
especially TLR7, has been shown to
contribute to murine and human SLE
pathogenesis. Thus, a large fraction of
patients with type I IFN-related diseases,
such as SLE and DM, might not benefit
from exclusively targeting the intrinsic
IFN pathway.ImmunityWe are also learning from Trex1/
mice that type I IFN can be the most
upstream event in autoimmunity devel-
opment. This has important implications
for the design of therapeutic strategies
across all IFN-related diseases. First,
a broad inhibition of type I IFN signaling,
including IFN-b, might be desirable over
the targeting of only IFN-a as currently
being tested in clinical trials. Second,
and most important, strategies aimed at
the early identification of type I IFN
activity might permit the blockade of
this pathway in susceptible individuals
before downstream, perhaps irreversible,
autoimmunity cascades are initiated. In
the era of genomics, this should be
a goal within reach.
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